drugset
drugset / Trial / NCT00544908

Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

NCT00544908 ↗

Phase 2 Terminated 7 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic cancer.

Timeline

Start
2007-09
Primary completion
2012-10
Completion
—

Outcome

Outcome not reported

Stopped: “Toxicity”

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule 70 mg Oral

Indications

malignant pancreatic neoplasm